Form 4: SpringWorks Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
A SpringWorks Therapeutics executive, Bhavesh Ashar, disposed of shares to cover tax obligations related to vesting restricted stock units.
Summary
- Bhavesh Ashar, Chief Commercial Officer at SpringWorks Therapeutics, disposed of company stock on three consecutive days.
- The transactions occurred on January 4th, 5th, and 6th of 2025.
- A total of 10,584 shares were disposed of to cover tax obligations related to vesting restricted stock units.
- The shares were sold at prices of $38.19 on January 4th and 5th, and $38.86 on January 6th.
- Following these transactions, Mr. Ashar directly owns 45,746 shares of SpringWorks Therapeutics stock.
Sentiment
Score: 5
Explanation: The document is a routine filing of stock transactions by an executive for tax purposes, which is neither positive nor negative for the company's outlook.
Industry Context
This is a routine filing related to stock transactions by company executives, which is common in publicly traded companies. It is not indicative of any specific company performance or outlook.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
- The transactions are related to tax obligations from vesting restricted stock units, which is a common practice for executive compensation.
- Similar filings are regularly made by executives at comparable biotech companies such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Incyte Corporation.
Stakeholder Impact
- The stock disposal has a minimal impact on shareholders as it is a routine transaction for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 01/04/2025 | First transaction date; 4,475 shares disposed of at $38.19. |
| 01/05/2025 | Second transaction date; 3,825 shares disposed of at $38.19. |
| 01/06/2025 | Third transaction date; 2,284 shares disposed of at $38.86. |
| 01/07/2025 | Date of signature for the Form 4 filing. |
Keywords
SpringWorks Therapeutics, stock disposal, insider trading, Form 4, executive, tax obligations, restricted stock units, SWTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.